Pasithea Therapeutics Corp.

FRC's fair value estimate for Pasithea Therapeutics Corp., and the rating behind it. KTTAW last traded at $0.0028; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Pasithea Therapeutics Corp.. Starting points for Pasithea Therapeutics Corp.: EPS -$3.03, beta 0.29 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Pasithea Therapeutics Corp.. Pasithea Therapeutics Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Pasithea Therapeutics Corp.. Trailing twelve-month EPS for Pasithea Therapeutics Corp. stands at -$3.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Pasithea Therapeutics Corp.. Pasithea Therapeutics Corp. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Pasithea Therapeutics Corp. valued side by side against its closest peers. Pasithea Therapeutics Corp. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Pasithea Therapeutics Corp., and how their positions are changing. At a $20,838 market value, institutional positions materially move Pasithea Therapeutics Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Pasithea Therapeutics Corp. executives and directors. Shares of Pasithea Therapeutics Corp. have traded between $0.0021 and $0.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Pasithea Therapeutics Corp.. Pasithea Therapeutics Corp. is a $20,838 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Pasithea Therapeutics Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Pasithea Therapeutics Corp.. Coverage tracks Pasithea Therapeutics Corp. within Biotechnology (Healthcare). Press releases and market coverage, newest first.